Although summer might not official start until Friday, it starts to feel like summer as soon as the highways north of Toronto get clogged every Friday and Sunday with people heading to and from their cottages. That being said, I think it's safe for me to do a summer edition of our random medtech article round-up and cleanse my inbox of some articles I had hanging around.
Check out the articles below for articles on cyber-security in relation to medtech, thoughts on austerity, and some updates on some of the top ten trends for medtech for 2013 that our VP Adrienne Lovink presented in February.
- I was recently catching up on the TV show ?Homeland,? and I came across an episode where a terrorist was able to hack into a US Vice President's pacemaker and alter the pacing to kill him. While my friends scoffed at how ridiculous this is, I pointed out that this actually is a valid concern in the medical device market these days?well, the potential to hack pacemakers (and insulin pumps) definitely exists, although I haven?t explicitly heard anyone bring up their potential as murder weapons. But as the world goes more electronic, companies definitely need to fundamentally change the way that they think about medical device manufacturing; having a cyber-security team will be key. Although medtech still has a long way to go in this area, longtime expert Kevin Fu says that there are ?glimmers of hope?.
- Oops, so apparently a simple Excel error (among a few more subjective errors) have taken down a paper that has been widely cited as the support for austerity measures in tough economic times. Although it doesn?t necessarily indicate that the opposite is true?that is, that austerity measures are conclusively bad in times of high debt?it does create space for more debate. I hope someone has some kind of breakthrough soon though before Greece gives up and exits the Eurozone.
- Another one of the trends that Adrienne Lovink discussed in February was the increasing commercialization of renal denervation. This trend hasn?t disappointed us, with this space continuing to generate significant media attention. For example, ReCor Medical has received approval for its next-generation Paradise system, while St. Jude Medical has begun enrolling patients in a trial to test its EnligHTN system in patients with less severe forms of hypertension. It also recently began enrolling in a new trial for its next-generation EnligHTN system. Additionally, a new study has suggested that these products might be able to help manage arrhythmias. Medtronic's CEO Omar Ishrak did, however, recently comment on how renal denervation has not been adopted as rapidly as anticipated in Europe.